GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA
Clinical trials for GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
First patients receive experimental pill targeting Hard-to-Treat cancers
Disease control Recruiting nowThis is the first-ever human study of an experimental pill called PLX-61639. It is being tested in adults with advanced cancers that have a specific genetic flaw (SMARCA4 mutation) and have stopped responding to standard treatments. The main goals are to find a safe dose and see …
Matched conditions: GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Plexium, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New immune drug targets Hard-to-Treat stomach and pancreatic cancers
Disease control Recruiting nowThis study is testing a new drug called ASP2138 for people with advanced stomach, gastroesophageal junction (GEJ), or pancreatic cancer. The drug works by guiding the body's own immune cells to attack cancer cells that have a specific marker called CLDN18.2. Researchers will test…
Matched conditions: GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC